OpGen reports preliminary 2022 revenue of $2.7M, within guidance; cash $7.4M; raises $7.5M in offering

CapForce Inc.

2022-FY EPS reported -$15.27 revenue$2,607,293

Preliminary full-year 2022 revenue approximately $2.7M, within most recent guidance range.
Cash position as of Dec 31, 2022: $7.4M; closed public offering on Jan 11, 2023 with gross proceeds $7.5M.
Implemented 1-for-20 reverse stock split to regain Nasdaq minimum bid price compliance.
UTI clinical trial achieved 96.4% sensitivity and 97.4% specificity; preparing FDA submission.
Signed second Acuitas AMR Gene Panel customer contract and installed first two systems.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CapForce Inc. reported year ended December 31, 2022 results: revenue approximately $2.7 million.

Period: year ended December 31, 2022
Revenue: approximately $2.7 million
Result: preliminary results

Exact text from the filing

Preliminary revenue for full year 2022 was approximately $2.7 million, which falls within the most recent guidance range the Company had provided in its Q3 earnings call.

View on SEC.gov

Browse all earnings releases →

CapForce Inc. filing history →

Source: SEC EDGAR

accession 0001079973-23-000095

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.